Research Efforts Abound in HER2-Positive Gastric and GEJ Cancers

Biomarkers play an essential role in the diagnosis and management of patients with gastric and gastroesophageal junction (GEJ) cancers, according to Rutika J. Mehta, MD, MPH, who added that many ongoing trials are working to identify the optimal treatment of subgroups whose tumors harbor different genomic alterations, such as HER2 mutations.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *